cyrilzakka/clinical-trials huggingface dataset:
Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

The purpose of this study is to compare how effective and how tolerable two different bowel preparation laxatives are for colonoscopy. The aim is to compare oral sulfate solution (OSS) to another laxative called 2L polyethylene glycol (PEG) solution to see which is more effective and more tolerable by individuals with IBD (Crohn's disease or Ulcerative colitis).


Eligibility Criteria:
Inclusion Criteria:

1. Crohn's disease or ulcerative colitis patients scheduled or about to be scheduled for colonoscopy.
2. Age \> 18 years
3. Out-patients

Exclusion Criteria:

1. Prior subtotal or total colorectal resection
2. Contraindications to use of 2L polyethylene glycol (2L-PEG) or Oral Sulfate Solution (OSS): Known renal insufficiency, congestive heart failure, cirrhosis, severe electrolyte imbalance.
3. Colonoscopy being repeated because of poor preparation in the preceding six months.
4. Allergies to the employed bowel preparations
5. Toxic megacolon, ileus, suspected or diagnosed bowel obstruction.
6. IBD patients thought to be too sick to undergo a full colonoscopy preparation in the opinion of the investigator/treating physician; hospitalized crohn's disease or ulcerative colitis patients.
7. Pregnancy
Caudal Corticosteroid vs. Dextrose Injection for Lumbosacral Radicular Pain.

Study comparing caudal prolotherapy to conventional steroid for chronic low back pain


Eligibility Criteria:
INCLUSION CRITERIA

1. Participants must satisfy diagnostic criteria for lumbar radicular pain at L4 nerve root level or below with consistent MRI or X ray findings.
2. Evidence of low back pain base upon one or more of the following:

   i. Lumbar back pain episodes lasting greater than 6 months and current pain level is greater than 6/10 on VAS.

   ii. Has received at lest 2 types of ancillary treatment (i.e. physical therapy, oral analgesia, acupuncture, etc.)
3. Men or women age greater than or equal to 18 years.
4. No significant alcohol use (7 or fewer drinks per week).
5. Patient has a history of at least 2 failed epidural CS injections.

EXCLUSION CRITERIA

1. Treatment risk factors including one or more of the following:

   i. Unstable or symptomatic cardiac complaints ii. Unstable or symptomatic respiratory complaints iii. Unable to reliably comprehend the protocol or reliably record data
2. Pregnancy. A serum pregnancy test must be performed and negative in all women of child bearing potential within 2 weeks prior to enrollment.
3. History of Malignancy
4. Any medical (i.e. malignancy, infection, thrombo-embolic states, autoimmune disease, polyneuropathy) or psychosocial condition that in the opinion of the investigator, could jeopardize the subject's participation, and compliance with the study criteria.
A Prospective Observational Study of Transcranial Doppler Ultrasound in the Assessment of Cerebral Blood Flow After Polyetheretherketone Cranioplasty

Polyetheretherketone has become one of the most important material choices for cranioplasty surgery. It has been shown that conventional ultrasound can be performed through the polyetheretherketone material for the examination of brain tissue and ventricular morphology. Transcranial doppler ultrasound can obtain good images of cerebral hemodynamic parameters in patients through polyetheretherketone-covered temporal window. This trial is a clinical prospective observational study in which cases treated with polyetheretherketone cranioplasty, and transcranial doppler ultrasonography is performed preoperatively and 10 days postoperatively, and data were collected mainly including bilateral hemodynamic parameters of middle cerebral artery(MCA), terminal internal carotid artery(TICA), (anterior communicating artery)ACA, and posterior cerebral artery(PCA) (Vs, Vd, Vm, PI index, RI index) from temporal window.


Eligibility Criteria:
Inclusion Criteria:

1. Age of 18 years or older;
2. Proposed polyetheretherketone cranioplasty;
3. Incomplete cranial bone in the lateral temporal window;
4. Signed informed consent for surgery and informed consent for research.

Exclusion Criteria:

1)Although cranioplasty is proposed, the cranial bone in the temporal region is intact.
Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections

The goal of this study is to test a new way to diagnose and track treatment of spine infections caused by the bacteria Staphylococcus aureus.

Ongoing Staphylococcus aureus (S. aureus) infections of the spine associated with orthopedic hardware implants elicit prominent immune responses against a repertoire of proteins characteristic of the invading pathogen. Antibodies specific for these antigens can be measured in the serum or in a novel sample created by culturing circulating Antibody Secreting Cells (ASC) in vitro where they create an analytic fluid called here "medium enriched for newly synthesized antibodies" (MENSA). The hypothesis of this study addresses three essential attributes of this analytic approach that can yield both a valuable tool for research on spinal infections and in the future, this can be developed a clinical tool for diagnosis and monitoring of therapeutic success in patients. By measuring the emergence of these signature antibodies in the serum and/or MENSA, the goals of this study are: 1) To differentiate between patients with an ongoing S. aureus infections, not just "general infection, in the spine using only blood samples; 2) To track the success (or failure) of therapeutic interventions; and 3) to distinguish spinal infections from S. aureus infections in other sites by the repertoire of antibodies that are elicited.

Eligibility Criteria:
Inclusion Criteria:

* patients with known or suspected spinal infections associated with spinal orthopedic implant(s);
* patients over 18 years of age and younger than 85;
* patients undergoing spinal revision surgery.

Exclusion Criteria:

* Diagnosed as immuno-compromised or immuno-suppressed based on medication use;
* On-going or previously diagnosed musculoskeletal infections associated non-spine hardware (e.g., prosthetic hip, prosthetic knee, prosthetic shoulder);
* Current diabetic foot ulcer/infection;
* Patients undergoing cancer treatment (including radiation and chemotherapies);
* Pregnancy;
* Absence of a spleen;
* Over the age of 85 or under the age of 18.
* Weigh less than 110 pounds, or for which it would otherwise be unsafe for them to undergo a blood draw.
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH. Study visits occurred at 4 week intervals for 12 weeks (with an additional visit at Week 11) with the key measure of efficacy being the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Two optional substudies were also a part of FREEDOM-M at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 12 and a genetics and biomarkers substudy with blood samples collected at Baseline and Week 12.

Patients who completed all assessments for 12 weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).


Eligibility Criteria:
Inclusion Criteria:

* Between 12 and 75 years of age, inclusive.
* Body weight at least 40 kg with a Body Mass Index \< 45
* PAH that is either idiopathic/heritable; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with HIV.
* Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.
* Baseline 6-minute walk distance between 200 and 425 meters, inclusive.
* Reliable and cooperative with protocol requirements.

Exclusion Criteria:

* Nursing or pregnant.
* Currently receiving an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or prostacyclin within 30 days of Baseline.
* PAH due to conditions other than noted in the above inclusion criteria.
* History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.
* Use of an investigational drug within 30 days of Baseline.
Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA

As we have previously reported, the primary cause of hip OA with accompanying joint pain might be bone alterations which can be microfracture. In order to prove it, it is planned that conservative treatment will be performed on the hip OA patients with accompanying joint pain for the first year. For the second year, if the patients still have joint pain, they will do non-weght bearing walk.


Eligibility Criteria:
Inclusion Criteria:

* Hip OA, Joint pain

Exclusion Criteria:

* Obvious radipgraphic fracture in hip joint,
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

The purpose of this study is to provide a central mechanism for monitoring access to peripheral blood, urine, and skin specimens obtained from CTCL, eczema, and atopic dermatitis patients to monitor:

* immunologic assays/flow cytometry
* tumor progression/regression
* genomic studies
* proteomic studies
* others germane to the advancement of CTCL treatment

Eligibility Criteria:
Inclusion Criteria:

* 18 or older
* able and willing to provide informed consent
* diagnosed with CTCL
* diagnosed with either atopic dermatitis or eczema

Exclusion Criteria:

* Lack of CTCL, atopic dermatitis, or eczema diagnosis in medical record
Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy

This study aim to observe and compare the change of alarmins such as high mobility group nucleosome-binding protein-1 (HMGN1), high mobility group proteins b1 (HMGb1), Interleukin (IL)-33 and their soluble receptors including soluble toll like receptor 4 (sTLR4) and soluble ST2 (sST2) during pulmonary lobectomy for cancer patients receiving volatile anesthesia or intravenous anesthesia under one-lung ventilation (OLV). By which, this study will preliminarily evaluate the correlation of alarmins and prognosis as well as the effect of inhalational and intravenous anesthesia on the prognosis of surgical patients.

During pulmonary lobectomy, as a result of OLV and surgical operation, patients can suffer from alveolar and systemic inflammatory response. Alarmin is endogenous peptide released by white blood cells and epithelial cells when the body undergo danger signal stimulation which can enhance immune response and has a double effect on tumor. Some alarmins and their soluble receptors such as HMGN1, HMGb1, IL-33 and their soluble receptors including sTLR4 and sST2 can be used as biomarkers for tumor progression. Previous studies have shown that sevoflurane anesthesia can reduce the level of inflammatory cytokines in bronchoalveolar lavage fluid. Meanwhile, the latest retrospective study indicated that the mortality of cancer patients receiving volatile anesthesia was significantly higher than that of intravenous anesthesia. At this stage, no study aimed to investigate the change of alarmins in broncho-alveoli and serum during OLV lung surgery and the possible effect of different anesthetics on them. Therefore, the investigators plan to enroll 40 patients with lung cancer receiving pulmonary lobectomy. Patients are randomly divided into sevoflurane volatile anesthesia group and propofol intravenous anesthesia group (n=20). Perioperative serum and bronchoalveolar lavage from ventilated lung are obtained, using ELISA method, to assay and compare the changes of alarmins such as HMGN1, HMGb1, IL-33 and their soluble receptors including sTLR4 and sST2 between two groups. All the patients will be followed up for 12 months. The correlation of alarmins and prognosis as well as the effect of volatile and intravenous anesthesia on the prognosis of patients will be preliminarily evaluated.

Eligibility Criteria:
Inclusion Criteria:

* American society of Anesthesiology (ASA) status I-II
* pathological diagnosis of lung cancer before surgery
* receive pulmonary lobectomy
* with normal lung function
* without heart failure (NYHA\>2), obstructive or restrictive lung disease
* no history of other malignancy tumor
* body mass index (Body mass, index, BMI) \< 35kg/m2
* no severe coagulopathy
* no severe systemic or pulmonary infection
* did not participate in other clinical trials

Exclusion Criteria:

* persistent smoking history
* immunosuppressive drug use 6 weeks before operation
* receive total pneumonectomy
* failure to complete treatment or follow-up
* severe adverse drug reactions
* severe postoperative complications
Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography

Despite the abundance of theories concerning the effects of chiropractic adjustments on brain function, this remains an understudies area for the profession.

Quantitative Electroencephalography (qEEG)is a technique that allows for an in-depth analysis of brain function. A normative database will be used to compare before, during and after effects of chiropractic adjustments on brain function. This will include usage of Low Resolution Electromagnetic Tomography (LORETA).

This study seeks to objectively document effects of chiropractic adjustments on brain function.


Eligibility Criteria:
Inclusion Criteria:

* Must be able to receive chiropractic adjustments

Exclusion Criteria:

* No benzodiazepine class drugs in study participants
* No use of medicines such as Sudafed (pseudoephedrine) or Nyquil (Doxylamine succinate)
* At least 30 days since last chiropractic adjustment
Evaluation of the Effectiveness of a Home Visiting Program for New Parents in New Mexico

The purpose of this study is to determine if children and mothers who participate in the First Born® Program (FBP) experience better outcomes than they would have in the absence of the program. The evaluation employs a randomized trial design to assess the effectiveness of the FBP in the Santa Fe County, NM, site. FBP is a home visitation program that uses clinically trained professionals to provide first-time parents with information, training, and access to resources designed to promote early childhood development. Services are free and may begin at any time during pregnancy or up to two months after the baby's birth and may continue until the child is three years old. In addition, a nurse postpartum home visit is offered to the parents of all participating newborns. The FBP model builds on other home visiting and prevention programs that have been shown to improve long-term outcomes of children and their families.


Eligibility Criteria:
Inclusion Criteria:

* First-time parent
* Mother is currently pregnant or child is less than two months old
* Lives within Santa Fe County, New Mexico
* Parent accepts referral to First Born Program

Exclusion Criteria:

* Child is not first born
* First-born child is two months or older
* Parent resides outside Santa Fe County
* Parent has not been referred to First Born Program
Endoscopic Ultrasound vs Percutaneous Route for Liver Biopsy

This study is to evaluate and directly compare the technical success, tissue quality, diagnostic efficacy and safety profile of Percutaneous and Endoscopic Ultrasound-guided Liver Biopsy.

Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.1 Since it was first performed in 1883, percutaneous (PC) liver biopsy has become routine practice and is usually performed under the guidance of real-time imaging using transabdominal ultrasound (US) or computed tomography (CT).1,2 However, in recent times, liver biopsy has been increasingly performed via transgastric or transduodenal routes under endoscopic ultrasound (EUS) guidance. The perceived advantages of performing EUS-LB compared to PC-LB are the ability to simultaneously assess other organs such as common bile duct and pancreas, access to both left and right lobes of the liver and the routine use of conscious sedation during EUS procedures.3 Although single arm cohort studies and retrospective comparative studies assessing the technical success, tissue quality and safety of these different liver biopsy modalities exist, currently there are no randomized trials comparing PC and EUS-guided LB.4-7

Eligibility Criteria:
Inclusion Criteria:

1. All patients referred for liver biopsy for any reason
2. Informed consent obtained from the patient
3. ≥ 18 years old
4. Able to undergo conscious sedation for EUS procedure

Exclusion Criteria:

1. \<18 years old
2. Unable to obtain informed consent from the patient
3. Medically unfit for sedation
4. Pregnant patients
5. Presence of a mass lesion in the liver requiring biopsy visualized on cross-sectional imaging
6. Irreversible coagulopathy as determined by platelet count \< 50,000 mm3 or International Normalized Ratio (INR) \> 1.5
7. Unable to stop anticoagulation or anti-platelet therapy for 5 days prior to the procedure
8. Hemophilia
9. Presence of an alternative etiology for elevated liver tests seen during liver biopsy, e.g. choledocholithiasis discovered during EUS examination
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.

This study will estimate the cumulative incidence of Zika infection at the end of the first epidemic in the French West Indies in a sample of patients followed for HIV infection.

Zika virus infection is expanding in all tropical and subtropical areas. The presence of Aedes albopictus in southern France raises concerns about the occurrence of outbreaks of indigenous Zika virus transmission. In this context, knowledge of the cumulative impact of the epidemic that affected the Caribbean in 2016 is an important issue for the management of future epidemics and modeling work. Since the Zika virus has not yet been circulated in the Lesser Antilles, the cumulative incidence rate can be estimated by conducting a general population seroprevalence survey at the end of the epidemic, or more simply within a cohort of patients regularly monitored and whose habitat is distributed throughout the study area. Thus, HIV-infected patients who benefit from regular clinical biological monitoring constitute a population sample perfectly adapted to the study of the emergence of the Zika virus in the French West Indies. The cumulative incidence of infection with the chikungunya virus after the 2014 epidemic has thus been estimated at 58% for Martinique and Guadeloupe using this method.

Eligibility Criteria:
Inclusion Criteria:

* Adult (\> 18 years pold)
* Followed for HIV infection at the 2 investigators centers (1 located at Martinique and 1 at Guadeloupe)
* Resident in Martinique /Guadeloupe (French West Indies) betwwen 01JAN2016 and 31DEC2016
* Affiliate or beneficiary of a social security scheme.
* Informed consent signed by the patient

Exclusion Criteria:

* Patient who has stayed in another area at risk of transmission of the Zika virus
Evaluation of Attitudes About Fertility

* Assess the attitudes and feelings of premenopausal Latin American women towards the risk of loss their fertility by adjuvant chemotherapy.
* Correlate the attitudes with other variables including age at diagnosis, already having children, number of children, level of instruction, marital status, frequency of menstrual cycle.

Eligibility criteria:

* Latin American women with evidence of cancer diagnosis at premenopausal status
* Over 18 years
* Agree to sign the informed consent
* No evidence of infertility.

Eligibility Criteria:
Inclusion Criteria:

* women with breast cancer diagnosis in premenopausal
* over 18 years
* signed informed consent

Exclusion Criteria:

* Evidence of infertility at diagnosis
Resourcefulness Group Intervention on Recovery and Quality of Life

The purpose of this study was to test the effects of resourcefulness group intervention on facilitating recovery and improving the quality of life in patients with chronic schizophrenia.

Purpose: This study aimed to explore the effects of resourcefulness group intervention on facilitating recovery and improving the quality of life in patients with chronic schizophrenia.

Methods: A longitudinal and interventional study with a quasi-experimental research design and convenience sampling were used in this study. Patients with chronic schizophrenia from a psychiatric hospital in northern Taiwan were recruited as subjects and were divided under random assignment into the experimental group and the control group with twenty participants in each. The twenty participants in the experiment group were further randomly distributed into two groups. Both received resourcefulness group intervention weekly for six weeks, while the control group followed regular care routines and underwent conventional treatment. All participants took a pretest before the intervention, the first posttest after six rounds of intervention, and the second posttest four weeks after the group intervention was completed. Data were collected using structured questionnaires, including the Chinese version of the Resourcefulness Scale (C-RS), the Chinese Questionnaire about the Process of Recovery (QPR), the WHOQOL-BREF Taiwan Version, and other personal information.

Eligibility Criteria:
Inclusion Criteria:

* Subjects who have been diagnosed with schizophrenia by a psychiatrist for more than two years and are currently receiving rehabilitation treatment in a chronic ward.
* Age between 20-64 years old.
* Those with stable conditions can communicate in Mandarin or Taiwanese.

Exclusion Criteria:

* Exclude clients with Intellectual Disabilities, Organic Encephalopathy, Substance-related and addictive disorders, Personality disorders, Dementia, Cancers, etc.
* Those who are unable to understand the contents of the consent form.
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).


Eligibility Criteria:
Inclusion Criteria:

1. A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks of study enrollment.
2. Ineligible to receive intensive chemotherapy for their disease.
3. Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities.

Exclusion Criteria:

1. Received previous treatment for AML.
2. Previously received Vidaza.
3. Received any other investigational agents within 30 days of first dose of study drug.
4. Uncontrolled intercurrent illness.
5. Had radiotherapy within 14 days prior to study enrollment.